Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Membrane-inhibiting Formula with Progestins for Fertility-Sparing in Endometrial Cancer
NCT06417736Recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- TCM (Traditional Chinese Medicine), Herbal formula
- Countries
- 1
01
Overview
Open-label, single-arm trial of membrane-inhibiting formula in endometrial carcinoma and endometrial hyperplasia (EH), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete Response Rate at 24 weeks. Started Dec 2023; status: recruiting.
02
Drugs
membrane-inhibiting formula
03
Conditions
endometrial carcinomaendometrial hyperplasia (EH)
Beyond the preview
Go deeper on NCT06417736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417736.